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Abstract
Background: Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Whilst surgery is the
mainstay of curative treatment, it is associated with significant risks. Surgical strategies for treating gastric cancer
should be based on evidence from systematic reviews of well-designed randomised controlled trials. However,
inconsistencies in the reporting of outcomes from these trials makes evidence synthesis unreliable. We present a
protocol for an international consensus study to develop a standardised set of outcomes and measurement tools –
a ‘core outcome set’ (COS) – to be used by all future trials examining therapeutic surgical interventions for gastric
cancer. The GASTROS study aims to standardise the reporting of outcomes in gastric cancer surgery trials through
an international consensus process of key stakeholders including health care professionals and patients.
Methods: The first of three stages in the study will identify a ‘long-list’ of potentially important outcomes to be
prioritised. These will be extracted from a systematic review of relevant academic literature and patient interviews.
Stage 2 will comprise an eDelphi survey which will consider the views of patients, nurse specialists and surgeons to
prioritise the most important outcomes. A meeting of stakeholder representatives will ratify the COS.
Stage 3 will focus on identifying appropriate instruments to measure the prioritised outcomes by means of quality
assessment of available measurement instruments and stakeholder consultation.
Discussion: This study aims to standardise the reporting of outcomes in future trials examining therapeutic surgical
interventions for gastric cancer. It is anticipated that standardisation of outcome reporting in these surgical effectiveness
trials will enhance the evidence base for clinical practice. Highlighting outcomes of greatest importance to patients will
ensure that their perspectives are central to research in this field.
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Background
Gastric cancer is one of the leading causes of cancer-
related deaths worldwide [1] and despite developments
in multimodal treatment approaches, overall survival
rates have not improved significantly over the last four
decades [2]. Surgery to remove part or all the stomach
continues to be the mainstay of treatment that offers a
potential cure; however, this is associated with significant
risks of short and long-term complications [3, 4]. Varia-
tions in surgical approaches aim to minimise these risks
without compromising the oncological resection of the
tumour. These variations can be broadly categorised into
those related to accessing the stomach (e.g. open, laparo-
scopic or robotic surgery) and those related to the extent
of surgery (e.g. partial or total gastrectomy, level of
lymphadenectomy and whether splenectomy is
required).
In principle, assessing the optimal surgical strategies for
gastric cancer should involve analyses of well-designed
and well-conducted randomised controlled trials (RCTs)
with systematic reviews and meta-analyses of data. How-
ever, trials are often methodologically heterogenous, report
and measure their outcomes differently and preclude com-
prehensive evidence synthesis. Consequently, strong recom-
mendations for clinical practice can seldom be made [5, 6].
In instances where trials may report the same outcomes,
the definitions of these outcomes are often inconsistent and
it is not known to what degree these outcomes may be rele-
vant to key stakeholders such as patients.
In preparing this protocol, a rapid review of RCTs
(published between January 2014 and January 2016)
examining therapeutic surgical interventions for gastric
cancer was undertaken using a structured search strat-
egy applied to MEDLINE and EMBASE via Ovid. In the
six trials identified, a total of 102 outcomes were re-
ported, only 15% of which were defined. No single
outcome was reported by every trial and only one trial
described patient-reported outcomes. No trial measured
quality of life after surgery.
Many groups have now demonstrated similar, wide-
spread inconsistencies in outcome reporting [7–10]. Con-
sequently, there has been a drive, with the support of
initiatives such as COMET (Core Outcomes Measurement
in Effectiveness Trials) and the Medical Research Council’s
Hubs for Trials Methodology Research, to standardise the
reporting of outcomes as an important step in improving
trial design and reducing research waste.
Aims and objectives
One solution to this problem is through the develop-
ment of a ‘core outcome set’ (COS). A COS is defined as
an agreed minimum set of outcomes that should be
measured and reported in all trials in a specific condi-
tion [11]. The aim of the GASTROS study (GAstric
cancer Surgery Trials Reported Outcomes Standardisa-
tion) is to develop a COS to be used by all trials examin-
ing therapeutic surgical interventions for gastric cancer,
which reflects the interests of both patients and health
care professionals.
The specific objectives include:
1. To determine the degree of variation in the
reporting of outcomes in the academic literature
2. To identify a list of potentially important outcomes
from published trials and trial protocols
3. To identify a list of potentially important outcomes
reported by patients, in semi-structured interviews,
who have been treated for gastric cancer, to augment
the list generated in item 2
4. To reach consensus regarding the most important
outcomes from the perspective of patients and
health care professionals into a COS
5. To identify appropriate outcome measurement
instruments (OMIs) to be used in the reporting of
the COS and at what time points the outcomes
should be measured
Methods
This study will draw its methodological principles from
recommendations developed by initiatives such as
COMET and COSMIN (COnsensus-based Standards for
the selection of health Measurement INstruments) and
modified where necessary and appropriate [12–17]. The
COMET initiative has been instrumental in propagating
the agenda for change in relation to outcomes reporting
internationally and has amassed a wealth of knowledge
and experience during the last 6 years. Whilst the field
of COSs is still relatively new, COMET is supporting the
development of hundreds of COSs demonstrated by over
400 completed, ongoing or planned studies across a wide
spectrum of clinical specialties referenced in its online
database [18]. COSMIN, whose focus lies on developing
rigorous methods of OMI selection, is working closely
with COMET and has developed standards for selecting
instruments used in the reporting of COSs [16].
Scope
This COS is primarily aimed at pragmatic trials examin-
ing therapeutic surgical interventions for gastric cancer.
The target population is male and female adults. We
foresee that the COS will also be beneficial for the
design of non-randomised studies and will inform the
design of databases and national audits by identifying
the priorities of patients and health care professionals.
Given that there is now a greater acceptance that the
management of gastric cancer is often multimodal (in-
volving a combination of surgical excision and chemo-
therapy or chemo-radiotherapy) [19], it may be argued
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that a COS would be more relevant if it were to encom-
pass all therapeutic interventions and not just surgical
ones. A structured search of the World Health Organi-
sation’s International Clinical Trials Registry Portal
(http://apps.who.int/trialsearch/, last accessed 3 August
2016) and ClinicalTrials.Gov (https://clinicaltrials.gov/,
last accessed 3 August 2016) has identified 24 ongoing
surgical gastric cancer trials planning to recruit ap-
proximately 11,000 patients. The rate at which these
surgical trials are being set up does not show signs of
slowing. As such, a surgically focused COS is highly
relevant given the research activity within this field.
Furthermore, there is a significant proportion of pa-
tients who do not require multimodal therapy due to
early stage disease or on the account that they are unfit
for additional therapies. In addition, given the large
variation in surgical practice that already exists, and
the range of therapeutic surgical interventions which
have been, and are being, investigated, we believe that a
surgically orientated COS is both desirable and neces-
sary. Nonetheless, our group recognises that future
work is required to develop a COS which will be rele-
vant to non-surgical interventions and this is within
our planned programme of work in conjunction with
endoscopic and medical and clinical oncology groups.
Definitions
The development of COSs by different groups has
highlighted some of the issues which arise with the in-
consistent use of nomenclature and definitions in a new
and developing research field. There are no widely
agreed definitions for several commonly used terms in
COSs; however, the COMET initiative recommends that
studies clearly define their own terms. Our definitions
are summarised in Table 1.
Stakeholder involvement
An important aspect of the GASTROS study design is
ensuring that key stakeholder opinion is represented at
every stage of the COS development. Our primary stake-
holder groups include patients (with ‘lived experience’ of
the condition and its management), surgeons (those
directly delivering and developing the clinical interven-
tions) and clinical nurse specialists (as they have an im-
portant dual role as health care professionals and patient
advocates). In addition to their participation highlighted
below (see ‘Study design’), representatives from each
group have been recruited to our Study Advisory Group
to support the general delivery of the study against its
stated objectives and ensure that the viewpoints of all
stakeholders are considered throughout the process.
Most surgical gastric cancer trials are undertaken in
the Far East where the incidence and prevalence is high-
est [1]. It is, therefore, essential that aspects of the COS
development take this international perspective into ac-
count. As such, representatives from all stakeholder
groups will be invited to participate in the eDelphi
survey. They will be drawn from a broad network of
national and international patient groups, charities, pro-
fessional associations and institutions. This is further
elaborated upon below (see ‘Dissemination and imple-
mentation strategy’).
Study design
The GASTROS study will be divided into three distinct
stages, summarised in Fig. 1:
Stage 1. Generation of ‘long-list’ of outcomes
Stage 2. Prioritisation of outcomes and finalisation of a
COS
Stage 3. Identification of OMIs
Stage 1. Generation of ‘long-list’ of outcomes
A long-list of potentially important outcomes will be
identified by means of a systematic academic literature
search and semi-structured patient interviews. This will
be followed by a consultation exercise to finalise a list of
outcomes to be prioritised by stakeholders in stage 2 of
the study.
Systematic academic literature search
A systematic review of randomised control trials (RCTs)
and protocols of RCTs examining therapeutic surgical
interventions for gastric cancer will be undertaken.
Table 1 Definition of terms used in the GAstric cancer Surgery Trials Reported Outcomes Standardisation (GASTROS) study
Core outcome set (COS) An agreed minimum set of outcomes that should be measured and reported in all trials in a
specific condition [11]
Outcome A unique endpoint which attempts to describe health-related changes that occur secondary to
a therapeutic intervention, e.g. hospital-acquired pneumonia
Outcome domain A collection of ‘outcomes’ which share common features, e.g. the outcome domain ‘respiratory
complications’ would include outcomes such as ‘pleural effusion’, ‘hospital-acquired pneumonia’
and ‘atelectasis’
Outcome measurement instrument (OMI) A method or tool used to measure an ‘outcome’ or an ‘outcome domain’
Outcome measurement instrument set A collection of OMIs which are used to measure outcome domains in a COS
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Systematic reviews of RCTs will be scrutinised to identify
publications not previously identified. We will limit our
analysis to RCTs as the primary purpose of the GASTROS
study is to influence future RCTs.
Abstracts will be screened by two researchers and
relevant publications identified. All reported outcomes
will be extracted verbatim in addition to definitions
and OMIs used. Validated Patient-reported Outcome
Measurements (PROMs), such as those used to report
‘quality of life’, will be critically reviewed to identify
further outcomes to be added to the ‘long-list’ [20].
Whilst overall quality of life may be deemed an out-
come that should be prioritised and included in a
COS, there may be components related to eating and
drinking, for example, that may be deemed important
outcomes within their own right.
Patient interviews
Previous reports have highlighted that patients often
have differing priorities and perspectives relating to out-
comes measured in trials [21–24]. To ensure that the
views of patients are adequately considered, a series of
semi-structured qualitative interviews, with patients who
have previously undergone surgery, will be undertaken.
All interviews will be audio-recorded, transcribed and
interrogated for themes which may supplement the out-
comes already gathered from the systematic academic
literature review. There is no ‘sample size’ calculation for
qualitative research. The total number of participants
should be guided by the concept of ‘saturation’, whereby
further interviews do not result in the identification of
new outcomes, and can range from between 5 and 50
participants [25, 26]. Based on the authors’ experience in
qualitative research methods in COS development, we
expect that between 15 and 30 patients will need to be
interviewed before ‘saturation’ is reached.
To ensure that a broad range of views are expressed
during the interviews, we aim to purposefully sample pa-
tients based on several characteristics. These include age,
sex, time since surgery, type of surgical approach (open or
minimally invasive) and whether patients have undergone
other perioperative therapies (chemotherapy or chemo-
radiotherapy).
Stage 2: Prioritisation of outcomes to finalise a COS
overview
Delphi surveys have been used in many COS projects to
reach consensus on the most important outcomes to
include [14, 27, 28]. One of the main benefits of this ap-
proach is that the views of all participants are equally
heard. This may not be the case in a face-to-face forum
where the views of one individual or group of partici-
pants may be more vociferously asserted. There is no
fixed methodological approach to undertake a Delphi
survey. Some groups have retained all potential outcome
domains in each round and used the participant re-
sponses to inform a final consensus meeting [27, 29],
whilst others have only retained outcome domains
deemed important in each round [28]. We intend to use
a hybrid approach over three rounds as described in
greater detail below. Following the Delphi survey, a
meeting of key stakeholder representatives will take
place to ratify the prioritised outcomes into a COS.
Organising the outcome list in preparation for stage 2
Once potentially important outcomes have been identi-
fied from the systematic review and patient interviews, a
final long-list of items will be compiled for the eDelphi
survey. We plan to recruit at least 100 participants and
so to minimise non-response and attrition between sur-
vey rounds, the initial number of items submitted to the
Delphi survey will need to be carefully managed. Previ-
ous COS developers have aimed for less than 100 initial
items for participants to prioritise [28]. To achieve this,
individual outcomes will be organised into ‘outcome
domains’ (Table 1) whilst ensuring that domains do not
become too broad. For example, the outcomes ‘hospital-
acquired pneumonia’, ‘pleural effusion’ and ‘atelectasis’
grouped together under the outcome domain ‘respiratory
complications’ may be appropriate, whereas grouping the
same outcomes under the domain ‘complications’ may be
too specific. The process of compiling and finalising the
outcome domains will be undertaken during a meeting of
key stakeholder representatives to ensure transparency.
This meeting will involve open discussion of each out-
come domain, including information relating to how the
outcome domain was formulated, to ensure that it is not
too broad or specific. An outcome domain will be
Fig. 1 GAstric cancer Surgery Trials Reported Outcomes
Standardisation (GASTROS) study overview
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admitted into the long-list for the subsequent eDelphi sur-
vey once agreement by majority regarding its appropriate-
ness has been reached by all stakeholder representatives.
Each item entered into the survey will be described in
lay terms with an additional scientific description. For
example, an ‘anastomotic leak’ may be described as ‘a
leak from the join between the stomach and the bowel’.
All item descriptions will be reviewed by the study group
and patient representatives. Items will be presented to
participants as collections with similar characteristics
(e.g. outcomes related to ‘adverse events’ or ‘technical
aspects of surgery’).
Participants and sample size
Representatives from our three primary stakeholder
groups – patients, clinical nurse specialists and sur-
geons – will be invited to participate in the Delphi
survey. Whilst there is no accepted or required ‘sam-
ple size’ requirement for a Delphi survey [30], we aim
to recruit at least 100 participants in total. The views
of each stakeholder group will be considered separately
which will enable intra- and inter-stakeholder group
variability to be explored. As explained previously, gastric
cancer is a worldwide disease, and as such, participants
will be sought internationally through a network of patient
groups, organisations, professional associations and cancer
institutes. The Delphi survey will be Internet-based; how-
ever, we will give participants the opportunity to complete
hard copies of the surveys so as not to exclude those with
limited Internet access or knowledge of the Internet.
Delphi survey
Round 1
A summary of the entire eDelphi survey process is illus-
trated in Fig. 2. Participants will be asked to score each
outcome domain on a 9-point scale proposed by the
GRADE group (http://www.gradeworkinggroup.org), in
which 1 to 3 signifies an outcome of ‘limited import-
ance’, 4 to 6 ‘important but not critical’, and 7 to 9
‘critical’. Round 1 will also provide participants with the
Fig. 2 Summary of the Delphi survey process
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opportunity to add further outcomes which they think
may be important. Any suggested outcomes deemed to
represent a new outcome domain by the study group
(following discussion and a majority decision) will be
added to the list for consideration in round 2. In
addition, prior to commencing round 1, participants
will be asked to enter demographic information about
themselves including country of residence and lan-
guage spoken. Surgeons will also be asked about the
volume of gastrectomies performed. This will enable
us to explore the impact of language, cultural vari-
ation and surgical experience in relation to the Delphi
survey responses.
Round 2
All items in addition to further new outcome domains
identified by participants in round 1 will be carried for-
ward for consideration in round 2. Descriptive statistics
will be used to summarise the scores from round 1 and
presented to participants. Participants will see the results
of their individual score for each outcome in addition to
the median score of each stakeholder group. The ration-
ale for showing participants the scores from other
groups is that it may improve consensus between the
stakeholder groups [15]. In addition, by carrying all
items forward from round 1, it may be possible to iden-
tify changes in scoring patterns as a result of viewing
other scores. Participants will be asked to score all items
once again using the 9-point scale.
Outcome domains which are scored ‘critical’ by greater
than 70% of participants from any stakeholder group,
and ‘unimportant’ by less than 15% of the group, will be
carried forward for further consideration in round 3.
The rationale for this threshold is that for an outcome
domain to be included in the COS, it requires agreement
by the majority regarding the critical importance of the
outcome, with only a small minority considering it to
have little importance. By carrying forward outcomes
relevant to at least one stakeholder group, participants
will be given another opportunity to reflect on the im-
portance of the outcome domain in the final round. As
the scope of this study is to identify the most important
outcomes, all other outcomes will be discarded.
Round 3
All retained outcomes will be summarised and partici-
pants will view both their individual scores and those
of the other groups before being asked to score items
a final time using the 9-point scale. Outcome do-
mains which are scored as ‘critical’ by greater than
70% and ‘unimportant’ by less than 15% of partici-
pants from all three groups will be retained for inclu-
sion in the COS.
Missing responses
If a participant does not complete a subsequent round
of the Delphi survey, their scores from previous rounds
will be counted as valid and retained in the study. Simi-
larly, if a participant fails to score a specific item during
a survey round, the answers to other items will be held
as valid and retained. The rate of missing responses will
be reported with the results of the Delphi survey.
Stakeholder meeting
Following the Delphi survey, a meeting of stakeholder
representatives will take place to review the results and
recommend the outcome domains as a COS.
Stage 3: Identification of outcome measurement tools
The final stage of the study will be based on guidance
set out by COMET and COSMIN in the selection of
appropriate measurement instruments for the outcome
domains included in the COS [16]. Our strategy is sum-
marised in Fig. 3 and is involves four stages;
1. Conceptual considerations
2. Finding existing OMIs
3. Quality assessment of OMIs
4. Recommendations on the selection of OMIs for a
COS and at what time points they should be used
1. Conceptual considerations
The first step involves identifying the scope of outcomes
to be measured. These will be identified in stage 2 of the
study. The scope of the COS has been described earlier
in this protocol.
2. Finding existing outcome measurement instruments
(OMIs)
Existing OMIs will be identified through several ap-
proaches. A structured search of MEDLINE and EMBASE
via Ovid will identify systematic reviews of OMIs for the
outcome domain concerned. If the systematic reviews are
of high quality and have undertaken a quality assessment
of the OMIs, then one OMI will be selected and presented
to a group of key stakeholder representatives at the end of
the process.
If there are no systematic reviews or they are of poor
quality, then a new or updated academic literature
search will be performed. We will search MEDLINE and
EMBASE via Ovid to identify studies of OMIs. We will
also interrogate reference lists and examine trials and
protocols identified in stage 1 of the GASTROS study to
identify further OMIs. Studies describing these OMIs
will be quality assessed as described below. OMIs identi-
fied through up-to-date systematic reviews where quality
assessments were not undertaken will also be assessed
by the predefined standards below.
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3. Quality assessment of OMIs
Each OMI-related study identified will undergo an
evaluation of its methodological quality using the COS-
MIN Checklist [31]. In addition, an evaluation of the
measurement properties of the OMI will be undertaken
against several predefined criteria [16] including ‘content
validity’ and ‘internal structure’. Content validity is
defined as ‘the degree to which the content of a meas-
urement instrument is an adequate reflection of the out-
come to be measured’. ‘Internal structure’ is comprised
of two aspects – ‘internal consistency’ (the degree of
interrelatedness among the items within the OMI) and
‘structural validity’ (the degree to which the scores of a
measurement instrument are an adequate reflection of
the dimensionality of the outcome to be measured). If ei-
ther ‘content validity’ or ‘internal structure’ are considered
poor or unknown, then the OMI will not be assessed
further. The results of this quality assessment will be com-
bined in a ‘best evidence synthesis’ exercise against criteria
defined by the COMET-COSMIN guidance.
It is also essential that OMIs are assessed in terms of
their feasibility of use. The COMET-COSMIN guidance
provides 17 different factors against which feasibility can
be assessed. These include ‘patient comprehensibility’,
‘interpretability’, ‘ease of administration’ and ‘completion
time’.
4. Generic recommendations on the selection of outcome
measurement instruments for a COS
An OMI will be recommended if it meets the following
criteria:
1. There is ‘high-quality’ evidence of ‘good’ content
validity and ‘good’ internal structure
and
2. The OMI is feasible to use
‘High-quality evidence’ is defined as consistent findings
in multiple studies of at least ‘good’ quality or in one study
of ‘excellent’ quality and a total sample size of 100 pa-
tients or more (see the COSMIN Checklist [31] for clarifi-
cation of the terms ‘good’ and ‘excellent’ quality).
It is possible that more than one OMI can be recom-
mended for an outcome domain. Conversely, it is pos-
sible that no OMIs are recommended. This scenario
may form the basis of future work to develop an OMI
for that domain.
Key stakeholder meeting
Following quality assessment for OMIs for each out-
come domain included in the COS, we will invite repre-
sentatives from each key stakeholder group to review the
evidence from this stage of study and ratify the recom-
mended OMIs as an OMI set. The primary function of
the stakeholder meeting is to ensure transparency of the
process, raise further questions and seek further clarifi-
cations (if any). The evidence considered will also inform
recommendations made through the stakeholder meet-
ing regarding when these OMIs should be used to meas-
ure the core outcomes.
Implementation strategy
A COS must be implemented widely within its clinical
field to have its intended benefit. Whilst grant-awarding
bodies and international research groups are increasingly
promoting the use of COSs, researchers must be willing
to incorporate them into trial designs. Our approach to
maximise the use of our COS is one of inclusion of key
Fig. 3 Process of identifying outcome measure instruments (OMIs)
for outcome domains in the core outcome set (COS)
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stakeholders in designing and delivering our study and
dissemination of the findings at every stage. Given that
most surgical gastric cancer trials are being undertaken
in the Far East, this inevitably means involvement of
international stakeholders. We are working with several
groups in South Korea, Japan and China in addition to
European and North and South American teams to en-
sure that this aspect of our study is facilitated. It is not
yet fully understood how language or cultural differences
may affect the results of consensus processes such as the
one we propose. Our study will provide the opportunity
to explore this question further.
Some of the steps that we have considered as part
of our dissemination and implementation strategy
include:
1. Registration of our study with COMET database
(http://www.comet-initiative.org/studies/details/
764?result=true)
2. Development of our study website
(www.GASTROSstudy.org) where key stakeholders
and interested parties can find regular updates and
register for participation
3. Development of our social media identity, e.g.
Twitter (@GASTROSstudy)
4. Widespread dissemination of our work at every stage
of the study through:
a. National and international scientific meetings
b. Journal publications
c. Patient events
d. Regular updates to our network of international
patient groups and charities, professional
associations and cancer centres
Engagement with, and ‘ownership’ of, the COS by
professional bodies will also be an important way to
facilitate the necessary regular review of the COS. Such
reviews are needed to ensure that individual outcomes
remain relevant and to add new outcomes as appropri-
ate. No recommendation exists regarding the time
interval between reviews, but we anticipate the need for
review within 3–5 years.
Discussion
There is no COS for trials examining surgical interven-
tions for gastric cancer. Through the GASTROS study,
we aim to standardise the definition, collection and
measurement of core outcomes which can be used to
compare future trials in this field. This will:
1. Improve the reliability of evidence synthesis on
which robust clinical guidelines can be based
2. Improve shared decision-making and the preopera-
tive consent process as outcomes from surgical
interventions which are relevant to both clinicians
and patients become more apparent
3. Better equip health care providers how best to
prioritise funding for interventions that reflect the
needs and priorities of patients
The COS will also inform non-RCT trial design and,
additionally, provide a minimum set of outcomes rele-
vant to key stakeholders which can be collected by
health care providers and organisations designing na-
tional audits and prospective databases.
The GASTROS study will also provide a platform for
future work which includes the development of PROMs
where they are deficient and the further development of
a COS which is relevant to multimodal therapies. Once
core outcomes are identified, work can also commence
on developing a minimum dataset of factors which can
influence these outcomes so that risk adjustment of out-
comes and ultimately the external validity of trials can
improve.
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